Drug Profile
Hepatitis B DNA vaccine - Oxxon Therapeutics
Alternative Names: Hi-8 HBV; pSG2.HBs/MVA.HBsLatest Information Update: 17 Jul 2009
Price :
$50
*
At a glance
- Originator Oxxon Therapeutics
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 03 May 2006 Final results from a phase IIa clinical trial in patients with chronic hepatitis B have been added to the Viral infections therapeutic trials section
- 03 May 2006 Oxxon has completed a phase IIa trial in hepatitis B in Poland and Serbia and Montenegro
- 21 Dec 2005 Phase-II clinical trials in Hepatitis B treatment in Poland (unspecified route)